Welcome to our dedicated page for Aclarion SEC filings (Ticker: ACONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclarion, Inc. filings document material events and governance for a commercial-stage healthcare technology issuer with Nasdaq-listed common stock and warrants. Recent Form 8-K reports cover capital actions such as a share repurchase authorization, executive finance leadership transition, employment agreement terms and Regulation FD communications.
The company's regulatory record also includes annual meeting and stockholder-vote disclosures, director elections, emerging growth company status and common stock information. These filings frame Aclarion's public reporting around its healthcare technology business, governance controls, officer appointments and capital-structure actions.
Gould Gregory A reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Financial Officer Gregory A. Gould received an equity compensation grant in the form of restricted stock units. On 6/11/2026 he was awarded 50,000 RSUs, each representing a contingent right to receive one share of Aclarion common stock.
All 50,000 RSUs are scheduled to vest on 6/1/2027, meaning the shares will be delivered if he remains eligible through that date. Any outstanding and unvested RSUs will also fully vest if a change of control occurs as defined in the company’s equity incentive plan. Following this grant, Gould holds 50,000 shares directly reported in this filing.
Ness Brent reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Executive Officer Brent Ness received an equity award in the form of 100,000 restricted stock units (RSUs) on June 11, 2026 under the company’s equity incentive plan. Each RSU represents a right to receive one share of ACON common stock.
The Form 4 shows the RSUs at a grant price of $0.00 per unit, reflecting a compensation award rather than a market purchase. All of the RSUs are scheduled to vest on June 1, 2027, and any unvested RSUs will fully vest if a change of control occurs as defined in the plan. Following this grant, Ness is shown holding 106,300 common shares directly.
Wesemann William reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director William Wesemann received an equity award of 20,000 restricted stock units. The RSUs were granted on 6/11/2026 under the company’s equity incentive plan and each unit represents one share of ACON common stock. All RSUs are scheduled to vest on 6/1/2027, with any unvested units fully vesting if a change of control occurs. Following this grant, Wesemann directly holds 21,563 shares of common stock.
Thramann Jeffrey John reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Executive Chairman Jeffrey John Thramann received a grant of 100,000 restricted stock units (RSUs) of common stock. Each RSU represents a contingent right to receive one share of Aclarion common stock.
All of the RSUs are scheduled to vest on June 1, 2027, and any outstanding unvested RSUs will fully vest if a change of control occurs as defined under the company’s equity incentive plan. Following this grant, Thramann holds 100,000 shares/RSUs directly.
Neal David K reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Neal David K reported an equity compensation grant. He received 20,000 restricted stock units (RSUs) on 6/11/2026 under the company’s equity incentive plan, each representing one future share of common stock. Following this award, he now holds 22,502 shares of common stock directly.
The filing notes that 100% of the RSUs vest on 6/1/2027, meaning he must remain eligible through that date to receive the underlying shares. Any unvested RSUs will also fully vest if there is a change of control as defined in the company’s equity incentive plan.
Deitsch Stephen reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Stephen Deitsch received an equity grant of 20,000 restricted stock units (RSUs). The award was granted on 6/11/2026 under Aclarion's equity incentive plan at no cash cost per unit, with each RSU representing the right to receive one share of common stock.
According to the terms, 100% of the RSUs will vest on 6/1/2027, and any unvested RSUs will fully vest if there is a change of control as defined in the company’s equity incentive plan. Following this grant, Deitsch holds 20,000 shares/units directly.
Aclarion, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected seven directors to serve until the 2027 annual meeting, with each nominee receiving more votes for than withheld.
Stockholders also ratified the appointment of Haynie & Company as the company’s independent registered public accounting firm, with 1,588,388 votes for, 20,623 against, and 10,985 abstaining. In addition, an amendment to Aclarion’s 2022 equity incentive plan was approved, receiving 453,431 votes for, 323,512 against, 1,302 abstentions, and 841,751 broker non-votes.
Aclarion, Inc. reported a larger net loss for the quarter ended March 31, 2026, while significantly strengthening its cash position through new equity financing. Revenue rose modestly to $21,140 from $18,991, driven mainly by more Nociscan reports sold in the U.K.
Operating expenses nearly doubled to $2.99 million, reflecting higher sales and marketing spending around the CLARITY Trial, greater research and development, and increased general and administrative costs such as investor relations and Delaware franchise taxes. Net loss widened to $2.85 million from $2.04 million, or $(1.34) per share.
Cash, cash equivalents and restricted cash increased to $19.03 million, supported by a January 2026 registered direct offering of common stock and pre-funded warrants that generated roughly $10.4 million in gross proceeds. The company expects its current cash to fund operations into the second half of 2027. Subsequent to quarter-end, the board approved a $2.5 million share repurchase program and adopted a stockholder rights agreement intended to discourage hostile accumulations of its stock.
Aclarion, Inc. director Scott Breidbart made an open-market purchase of Common Stock. On May 12, 2026, he bought 5,664 shares at a price of $3.18 per share in a public market transaction. Following this trade, his directly held position stands at 5,664 shares.
Aclarion, Inc. director Neal David K completed an open-market purchase of 2,500 shares of Aclarion common stock on May 11, 2026. The shares were bought at an average price of $3.10 per share. Following this transaction, he directly holds 2,502 common shares of Aclarion.